At the recently concluded American Society of Clinical Oncology meeting, Gilead Sciences, Inc. and Arcus Biosciences, Inc. joined the ranks of firms developing combinations of PD-1 and PD-L1 inhibitors with monoclonal antibodies targeting TIGIT that have not yet lived up to everyone’s expectations in lung cancer.
As Gilead’s PD-1/TIGIT Trial Falls Short, Oncologists Say Better Biomarkers Needed
The ARC-7 trial showed a progression-free survival benefit in NSCLC, but the PFS benefit for zimberelimab/domvanalimab wasn’t as big as analysts and oncologists had hoped.
More from ASCO
• By
Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.
• By
The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers.
• By
Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.
• By
US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.
More from Conferences
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.